Literature DB >> 2572903

Plasmodium vivax resistance to chloroquine?

K H Rieckmann1, D R Davis, D C Hutton.   

Abstract

Two soldiers continued weekly prophylaxis with 300 mg chloroquine base on their return to Australia from Papua New Guinea but were not protected against Plasmodium vivax malaria. Both had symptoms and parasitaemia although plasma concentrations of chloroquine were considerably higher than those regarded as adequate for suppression of vivax malaria. Parasitaemia did not clear after one of the patients was treated with 600 mg chloroquine base. The results suggest the emergence of strains of P vivax with a reduced susceptibility to chloroquine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572903     DOI: 10.1016/s0140-6736(89)91792-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  157 in total

Review 1.  The evolution of tafenoquine--antimalarial for a new millennium?

Authors:  W Peters
Journal:  J R Soc Med       Date:  1999-07       Impact factor: 5.344

2.  Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand.

Authors:  Moritz Treiber; Gunther Wernsdorfer; Ursula Wiedermann; Kanungnit Congpuong; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2011-09-22       Impact factor: 1.704

Review 3.  History, dynamics, and public health importance of malaria parasite resistance.

Authors:  Ambrose O Talisuna; Peter Bloland; Umberto D'Alessandro
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

4.  Blocking effect of a monoclonal antibody against recombinant Pvs25 on sporozoite development in Anopheles sinensis.

Authors:  Sung-Ung Moon; Hyung-Hwan Kim; Tong-Soo Kim; Kyung-Mi Choi; Chang-Mi Oh; Yong-Joo Ahn; Seo-Kyoung Hwang; Youngjoo Sohn; E-Hyun Shin; Hyuck Kim; Hyeong-Woo Lee
Journal:  Clin Vaccine Immunol       Date:  2010-06-16

5.  Synergism between pyronaridine and retinol in Plasmodium vivax in vitro.

Authors:  Julia Riedl; Gunther Wernsdorfer; Kanungnit Congpuong; Ursula Wiedermann; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2010-10       Impact factor: 1.704

6.  Variations in frequencies of drug resistance in Plasmodium falciparum.

Authors:  P K Rathod; T McErlean; P C Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 7.  Chloroquine resistance in Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 8.  Antimalarial pharmacokinetics and treatment regimens.

Authors:  N J White
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

9.  Susceptibility to chloroquine, mefloquine and artemisinin of Plasmodium vivax in northwestern Thailand.

Authors:  Birgit Woitsch; Gunther Wernsdorfer; Kanungnit Congpuong; Chaiporn Rojanawatsirivet; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

10.  Chloroquine-Primaquine Therapeutic Efficacy, Safety, and Plasma Levels in Patients with Uncomplicated Plasmodium vivax Malaria in a Colombian Pacific Region.

Authors:  Esteban Mesa-Echeverry; Mayra Niebles-Bolívar; Alberto Tobón-Castaño
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.